Morning Overview on MSN
The FDA cleared Xocova, the first oral antiviral to prevent COVID-19 after exposure, in a five-day pill course shown to cut infections in a phase 3 trial
Households where someone tests positive for COVID-19 now have an oral drug option to protect the people around them. The FDA ...
Announcing a new article publication for Zoonoses journal. Varicella-zoster virus (VZV) is a clinically important human ...
Live Science on MSN
A cheap arthritis drug shows promise treating RSV in early study
An arthritis drug reduces the amount of RSV in human respiratory cells, but experts say it's too early to say if it will ...
An at-home pill against coronavirus halves the chance that people newly diagnosed with COVID-19 will land in the hospital or ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine New antiviral drugs in development could offer the ...
The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.
Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir available ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Researchers at McMaster University have found a class of well-known antiviral drugs could be part of a one-two punch to treat seasonal influenza and prevent a flu pandemic when used in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results